News
-
15 January 2019
Immunocore names David Berman as Head of R&D -
4 January 2019
Immunocore appoints Bahija Jallal as Chief Executive Officer -
19 November 2018
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech -
26 October 2018
Immunocore CEO Andrew Hotchkiss appointed to the Board of the BIA -
5 September 2018
Immunocore strengthens IP position in the field of TCR-based therapeutics -
20 August 2018
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours -
16 July 2018
Immunocore Announces Management Change -
4 June 2018
Immunocore Presents New IMCgp100-102 Data that Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma -
22 May 2018
Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting -
21 May 2018
Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards